Skip to main content
. 2021 Feb 22;26(5):362–e724. doi: 10.1002/onco.13689
Number of Patients, Male 33
Number of Patients, Female 9
Stage Stage IV: 42 (100%)
Age Median (range): 56.6 (36–78) years
Number of Prior Systemic Therapies Median (range): 3 (2–7)
Performance Status: ECOG

0 — 19

1 — 19

2 — 3

3 — 0

Unknown — 0

Cancer Types or Histologic Subtypes

BRAF mutated — 0

BRAF wild type — 12 (31%)

KRAS mutated — 21 (50%)

KRAS wild type — 18 (42.9%)

Microsatellite instability (MSI) high — 0

MSI low — 1 (2.4%)

MSI stable — 12 (28.6%)

Other See Table 2 and Figure 2.